Imunovakcina - Company finances
|
EUR
|
2021
From: 2021-02-23
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | - | - | 85,770 | 150,982 | 289,046 |
| Profit before tax | - | - | - | - | - |
| Net profit | -14,440 | -47,504 | 19,741 | 70,488 | 181,890 |
| Equity | -11,940 | -46,944 | -27,203 | 43,285 | 225,175 |
| Liabilities | 65,259 | 70,409 | 60,111 | 106,717 | 150,885 |
| Non-current assets | 0 | 0 | 3,000 | 3,000 | 3,000 |
| Current assets | 53,319 | 23,465 | 29,908 | 148,002 | 373,060 |
| Total assets | 53,319 | 23,465 | 32,908 | 151,002 | 376,060 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 9,426 | 46,205 | 58,579 |
| Social insurance contributions | - | - | - | 1,321 | 1,909 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | - | - | +76.0% | +91.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -27.1% | -202.4% | 60.0% | 46.7% | 48.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | 162.8% | 80.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | 23.0% | 46.7% | 62.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | 2.5 | 0.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | 39,586 | 50,327 | 93,746 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Imunovakcina - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-02-10 | 2025-02-10 | 1.10 |
| 2025-01-16 | 2025-02-03 | 1.10 |
| 2025-01-02 | 2025-01-14 | 1.10 |
| 2024-12-22 | 2024-12-31 | 1.10 |
| 2024-12-17 | 2024-12-20 | 1.10 |
| 2024-11-18 | 2024-12-02 | 1.10 |
| 2024-10-16 | 2024-11-05 | 1.10 |
| 2024-09-17 | 2024-09-30 | 1.10 |
| 2024-08-19 | 2024-09-04 | 1.10 |
| 2024-07-24 | 2024-08-01 | 1.10 |
| 2024-04-16 | 2024-04-17 | 1338.23 |
Imunovakcina - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Imunovakcina, UAB (code 305703660) is a Private Limited Liability Company engaged in research and development in medical sciences. In 2025, the company generated €289.0K in revenue and €181.9K in net profit, corresponding to a 62.9% profit margin. Revenue rose by 91.4% year on year and by 237.0% over two years, indicating a strong growth trajectory from €85.8K in 2023 to €151.0K in 2024 and then to €289.0K in 2025. Net profit followed the same pattern, increasing from €19.7K in 2023 to €70.5K in 2024 and €181.9K in 2025. The balance sheet also strengthened materially: total assets reached €376.1K in 2025, equity was €225.2K, and liabilities were €150.9K. The equity ratio stood at 59.9% and debt-to-equity at 0.67. Asset turnover was 0.77x, while revenue per employee amounted to €96.3K and profit per employee to €60.6K.